April 2, 2019 8:09am

Remember, “when one feels the pain, you know you’re not dead yet”

… Trade, my point is to pass on warning analysis or Intel so no dollar is left on the table but, in your portfolio!

Pre-open indications: 2 BUY, 4 SELLs and 3 TRADES

News: Sangamo Therapeutics (SGMO) and Pfizer (PFE) announced "encouraging" results from a P1/2 study of SB-525 gene therapy for the treatment of severe hemophilia A. The companies said SB-525 was generally well tolerated and demonstrated a dose-dependent increase in Factor VIII levels across the four dosage cohorts … read more

 

You’d be reading if you were a subscriber!

My pre-open focus is indication analysis. An indication can be a development of almost any kind. Specifically, it may be a confirmed fact, a possible fact, or an absence of “something”, a fragment of information or even an observation!

 

Dow futures are DOWN -0.02% (-5 points), S&P futures are UP +0.04% (+1 points) and NASDAQ futures are UP +0.05% (+4 points)

 

U.S. stock futures were under pressure Tuesday, despite data from the U.S. and China showing a rebound in manufacturing activity

European stocks were mixed as Brexit troubles roll-on, as stronger-than-anticipated factory activity surveys from the U.S. and China eased concerns over the global economy

Asia Pacific markets advanced following gains in U.S. markets, as concerns over a possible global economic slowdown eased, but stocks gave up some of their gains in late-morning and afternoon trade

Data docket: the U.S. durable goods report is due to be released Tuesday at 8:30 a.m. ET.

 

Tuesday’s indications in the pre-market:

The iShares Nasdaq Biotechnology (IBB) is NOT indicating;

The SPDR S&P Biotech ETF (XBI) is NOT indicating;

The Health Care Select Sector SPDR ETF (XLV) is NOT indicating;

The iShares Russell 2000 (IWM) is indicating a POSITIVE +0.01% UPSIDE;

 

Henry’omics:

Sector equities should be meeting resistance in today’s market; we have had many positive sessions and a run on the upside could be in-store!

Trading is pulling the strings of “out” universe and profiting on the run-up is on the minds of many.

 

From Monday’s closing bell post, “the clock is ticking as Q2 begins and I’m worried; Q1 suffered the constant battle of the oversold versus the overbought as “earnings’ releases unbalanced share values. Slowly losses have been made up yet, the battle for pricing sustainability continues unabated while volume remains low.”

Last night, Monday:

  • Range of the 23 upside was +0.11% (ONCE) to +21.46% (RENE.L) while the 19 downside ranged from -0.05% (OSIR) to -6.38% (BSTG).
  • 3 out of the 23 upside had higher (than the 3 month average) volume
  • 4 out of the 19 downside experienced greater volume (than the 3 month average)
  • April started with 1 positive close;
  • In March’s 21 sessions, there were 7 negative and 14 positive closes;
  • In the last five (5) sessions, the IBB has been up +3.32% (down 1 session, last Wednesday -1.39%)
  • Out of the last 5 sessions, 4 were positive; 6 of the last 10 were positive and 10 out of the last 15 sessions were positive – I perceive a decline, its coming!

 

Companies in my headlights – It’s your decision; I provide an idea and context:

bluebird bio (BLUE) closed up +$0.85 to $158.18 and after six (6) sessions has approximately $11.30 in upside and the chart looks “toppy”; I’d be reaping any profit because one doesn’t know what the future brings while SGMO has news – SELL;

Biostage (BSTG) closed down -$0.15 to $2.20 with 7,759 shares traded. BSTG ended FY18 with $1.4 M in cash and spends $1.7 M per quarter (lately) – they are BROKE and probably scrounging for cash which brings dilution and price depreciation – SELL;

CRISPR Therapeutics (CRSP) closed down -$0.27 to $35.45 and has a negative -$0.98 or -2.78% aftermarket indication – TRADE;

Editas Medicine (EDIT) closed up +$0.26 to $24.71 and has a positive +$0.32 or +1.29%) aftermarket indication – TRADE;

Intellia Therapeutics (NTLA) closed up +$0.05 to $17.13 and has a negative -$0.33 or -1.93% aftermarket indication – TRADE;

MiMedx Group (MDXG) closed up +$0.20 to $3.71 having seen $3.51 on Friday, $3.60 on Thursday, $3.56 on Wednesday, $3.55 on Tuesday and $3.45;  last Monday after the previous Friday’s $3.41 and $3.30 on the previous Thursday – SELL;

ReNeuron Group (RENE.L) closed up +$22.00 or +21.46% to $124.50 after Friday’s $102.50, Thursday’s $90.50, Wednesday’s $75.00 and last Tuesday’s $71.50. It’s getting too rich – SELL;

Sangamo Therapeutics (SGMO) closed down -$0.01 to $9.53 and has a positive +$0.87 or +9.13% on news after the genomic medicine company and Pfizer (PFE) announced "encouraging" results from a P1/2 study of SB-525 gene therapy for the treatment of severe hemophilia A. The companies said SB-525 was generally well tolerated and demonstrated a dose-dependent increase in Factor VIII levels across the four dosage cohorts. Based on the study's results, the Safety Monitoring Committee (SMC) recommended expansion at a specific dose. These interim results suggest that SB-525 may be well-tolerated and may prove to have the predictability and sustained treatment effect that can bring clinical benefit in patients with hemophilia A – BUY;

Verastem Oncology (VSTM) closed down -$0.01 to $2.95 and has a positive +$0.04 or +1.36% aftermarket indication. I am still of the opinion that VSTM is OVERSOLD – BUY;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.